TSE:4516Pharmaceuticals
The Bull Case For Nippon Shinyaku (TSE:4516) Could Change Following New Duchenne mRNA Option Deal - Learn Why
Nippon Shinyaku Co., Ltd. recently entered into an option agreement with Elixirgen Therapeutics to potentially secure exclusive worldwide rights to develop and commercialize EXG-7001, an investigational mRNA-based therapy for Duchenne muscular dystrophy that is currently in preclinical development ahead of planned U.S. trials.
This move deepens Nippon Shinyaku’s rare-disease focus by targeting full-length dystrophin expression regardless of mutation type, potentially broadening the...